RESUMEN
INTRODUCTION: The coronavirus disease 2019 (COVID-19) pandemic has put tremendous pressure on healthcare systems. Most transcatheter aortic valve implantation (TAVI) centres have adopted different triage systems and procedural strategies to serve highest-risk patients first and to minimise the burden on hospital logistics and personnel. We therefore assessed the impact of the COVID-19 pandemic on patient selection, type of anaesthesia and outcomes after TAVI. METHODS: We used data from the Netherlands Heart Registration to examine all patients who underwent TAVI between March 2020 and July 2020 (COVID cohort), and between March 2019 and July 2019 (pre-COVID cohort). We compared patient characteristics, procedural characteristics and clinical outcomes. RESULTS: We examined 2131 patients who underwent TAVI (1020 patients in COVID cohort, 1111 patients in pre-COVID cohort). EuroSCORE II was comparable between cohorts (COVID 4.5⯱ 4.0 vs pre-COVID 4.6⯱ 4.2, pâ¯= 0.356). The number of TAVI procedures under general anaesthesia was lower in the COVID cohort (35.2% vs 46.5%, pâ¯< 0.001). Incidences of stroke (COVID 2.7% vs pre-COVID 1.7%, pâ¯= 0.134), major vascular complications (2.3% vs 3.4%, pâ¯= 0.170) and permanent pacemaker implantation (10.0% vs 9.4%, pâ¯= 0.634) did not differ between cohorts. Thirty-day and 150-day mortality were comparable (2.8% vs 2.2%, pâ¯= 0.359 and 5.2% vs 5.2%, pâ¯= 0.993, respectively). CONCLUSIONS: During the COVID-19 pandemic, patient characteristics and outcomes after TAVI were not different than before the pandemic. This highlights the fact that TAVI procedures can be safely performed during the COVID-19 pandemic, without an increased risk of complications or mortality.
RESUMEN
BACKGROUND: Current guidelines on coronary anomalies are primarily based on expert consensus and a limited number of trials. A gold standard for diagnosis and a consensus on the treatment strategy in this patient group are lacking, especially for patients with an anomalous origin of a coronary artery from the opposite sinus of Valsalva (ACAOS) with an interarterial course. AIM: To provide evidence-substantiated recommendations for diagnostic work-up, treatment and follow-up of patients with anomalous coronary arteries. METHODS: A clinical care pathway for patients with ACAOS was established by six Dutch centres. Prospectively included patients undergo work-up according to protocol using computed tomography (CT) angiography, ischaemia detection, echocardiography and coronary angiography with intracoronary measurements to assess anatomical and physiological characteristics of the ACAOS. Surgical and functional follow-up results are evaluated by CT angiography, ischaemia detection and a quality-of-life questionnaire. Patient inclusion for the first multicentre study on coronary anomalies in the Netherlands started in 2020 and will continue for at least 3 years with a minimum of 2 years of follow-up. For patients with a right or left coronary artery originating from the pulmonary artery and coronary arteriovenous fistulas a registry is maintained. RESULTS: Primary outcomes are: (cardiac) death, myocardial ischaemia attributable to the ACAOS, re-intervention after surgery and intervention after initially conservative treatment. The influence of work-up examinations on treatment choice is also evaluated. CONCLUSIONS: Structural evidence for the appropriate management of patients with coronary anomalies, especially (interarterial) ACAOS, is lacking. By means of a structured care pathway in a multicentre setting, we aim to provide an evidence-based strategy for the diagnostic evaluation and treatment of this patient group.
RESUMEN
BACKGROUND: In patients with coronary artery disease, treated with durable polymer-coated drug-eluting stents, the life-long presence of the polymer might delay arterial healing. Novel very thin strut biodegradable polymer stents, which leave only a bare metal stent after polymer resorption, might improve long-term outcome. We investigated in allcomers the safety and efficacy of three stents eluting either everolimus, sirolimus, or zotarolimus, often clinically used but never compared, of which the biodegradable polymer everolimus-eluting stent was never before assessed in allcomers. METHODS: The large-scale, investigator-initiated, multicentre, assessor and patient blinded, three-arm, randomised, BIO-RESORT non-inferiority trial was done at four clinical sites in the Netherlands. All-comer patients were aged 18 years or older, capable of providing informed consent, and required a percutaneous coronary intervention with drug-eluting stent implantation according to clinical guidelines or the operators' judgment. Exclusion criteria were: participation in another randomised drug or device study before reaching the primary endpoint of that study; planned surgery necessitating interruption of dual antiplatelet therapy within the first 6 months; known intolerance to components of the investigational product or medication required; uncertainty about the adherence to follow-up procedures or an assumed life expectancy of less than 1 year; or known pregnancy. Web-based computer-generated allocation sequences randomly assigned patients (1:1:1) to treatment with very thin strut biodegradable polymer everolimus-eluting or sirolimus-eluting stents (which differ substantially in type, amount, distribution, and resorption speed of their respective coating), or thin strut durable polymer zotarolimus-eluting stents. The primary endpoint was a composite of safety (cardiac death or target vessel-related myocardial infarction) and efficacy (target vessel revascularisation) at 12 months of follow up with a very thin strut biodegradable polymer of either everolimus-eluting or sirolimus-eluting stents, compared with durable polymer zotarolimus-eluting stents, analysed by intention to treat (non-inferiority margin 3·5%). This trial was registered with ClinicalTrials.gov, number NCT01674803. FINDINGS: From Dec 21, 2012, to Aug 24, 2015, 3514 patients were enrolled and analysed, of whom 2449 (70%) had acute coronary syndromes, which included 1073 (31%) ST-elevation myocardial infarctions. 12 month follow-up of 3490 (99%) patients (three lost to follow-up; 21 withdrawals) was available. The primary endpoint was met by 55 (5%) of 1172 patients assigned to everolimus-eluting stents, 55 (5%) of 1169 assigned to sirolimus-eluting stents and 63 (5%) of 1173 assigned to zotarolimus-eluting stents. Non-inferiority of the everolimus-eluting stents and sirolimus-eluting stents compared with zotarolimus-eluting stents was confirmed (both -0·7% absolute risk difference, 95% CI -2·4 to 1·1; upper limit of one sided 95% CI 0·8%, pnon-inferiority<0·0001). Definite stent thrombosis (defined by the Academic Research Consortium) occurred in four (0·3%) of 1172 patients who were allocated to everolimus-eluting stents, four (0·3%) of 1169 patients who were allocated to sirolimus-eluting stents, and three (0·3%) of 1173 patients who were allocated to zotarolimus-eluting stents (log-rank p=0·70 for both comparisons with zotarolimus-eluting stents). INTERPRETATION: At 12 month follow-up, both very thin strut drug-eluting stents with dissimilar biodegradable polymer coatings (eluting either everolimus or sirolimus) were non-inferior to the durable polymer stent (eluting zotarolimus) in treating allcomers with a high proportion of patients with acute coronary syndromes. The absence of a loss of 1 year safety and efficacy with the use of these two biodegradable polymer-coated stents is a prerequisite before assessing their potential longer-term benefits. FUNDING: Biotronik, Boston Scientific, and Medtronic.
Asunto(s)
Síndrome Coronario Agudo/cirugía , Antibacterianos/uso terapéutico , Stents Liberadores de Fármacos , Everolimus , Sirolimus/análogos & derivados , Sirolimus/uso terapéutico , Implantes Absorbibles , Anciano , Antibacterianos/administración & dosificación , Enfermedad Coronaria/cirugía , Femenino , Humanos , Inmunosupresores/uso terapéutico , Masculino , Persona de Mediana Edad , Países Bajos , Intervención Coronaria Percutánea/instrumentación , Intervención Coronaria Percutánea/métodos , Polímeros , Sirolimus/administración & dosificación , Sirolimus/análisis , Resultado del TratamientoRESUMEN
BACKGROUND: As life expectancy increases, the population of older individuals with coronary artery disease and frailty is growing. We aimed to assess the impact of patient-reported frailty on the treatment and prognosis of elderly early survivors of non-ST-elevation acute coronary syndrome (NSTE-ACS). METHODS: Frailty data were obtained from two prospective trials, POPular Age and the POPular Age Registry, which both assessed elderly NSTE-ACS patients. Frailty was assessed one month after admission with the Groningen Frailty Indicator (GFI) and was defined as a GFI-score of 4 or higher. In these early survivors of NSTE-ACS, we assessed differences in treatment and 1-year outcomes between frail and non-frail patients, considering major adverse cardiovascular events (MACE, including cardiovascular mortality, myocardial infarction, and stroke) and major bleeding. RESULTS: The total study population consisted of 2192 NSTE-ACS patients, aged ≥70 years. The GFI-score was available in 1320 patients (79 ± 5 years, 37% women), of whom 712 (54%) were considered frail. Frail patients were at higher risk for MACE than non-frail patients (9.7% vs. 5.1%, adjusted hazard ratio [HR] 1.57, 95% confidence interval [CI] 1.01-2.43, p = 0.04), but not for major bleeding (3.7% vs. 2.8%, adjusted HR 1.23, 95% CI 0.65-2.32, p = 0.53). Cubic spline analysis showed a gradual increase of the risk for clinical outcomes with higher GFI-scores. CONCLUSIONS: In elderly NSTE-ACS patients who survived 1-month follow-up, patient-reported frailty was independently associated with a higher risk for 1-year MACE, but not with major bleeding. These findings emphasize the importance of frailty screening for risk stratification in elderly NSTE-ACS patients.
Asunto(s)
Síndrome Coronario Agudo , Anciano Frágil , Fragilidad , Humanos , Anciano , Femenino , Masculino , Fragilidad/epidemiología , Fragilidad/diagnóstico , Síndrome Coronario Agudo/epidemiología , Anciano de 80 o más Años , Estudios Prospectivos , Anciano Frágil/estadística & datos numéricos , Sistema de Registros , Medición de Resultados Informados por el Paciente , Estudios de Seguimiento , Resultado del Tratamiento , Infarto del Miocardio sin Elevación del ST/epidemiología , Infarto del Miocardio sin Elevación del ST/mortalidadRESUMEN
BACKGROUND: The predictive performance of the models FRANCE-2 and ACC-TAVI for early-mortality after Transcatheter Aortic Valve Implantation (TAVI) can decline over time and can be enhanced by updating them on new populations. We aim to update and internally and temporally validate these models using a recent TAVI-cohort from the Netherlands Heart Registration (NHR). METHODS: We used data of TAVI-patients treated in 2013-2017. For each original-model, the best update-method (model-intercept, model-recalibration, or model-revision) was selected by a closed-testing procedure. We internally validated both updated models with 1000 bootstrap samples. We also updated the models on the 2013-2016 dataset and temporally validated them on the 2017-dataset. Performance measures were the Area-Under ROC-curve (AU-ROC), Brier-score, and calibration graphs. RESULTS: We included 6177 TAVI-patients, with 4.5% observed early-mortality. The selected update-method for FRANCE-2 was model-intercept-update. Internal validation showed an AU-ROC of 0.63 (95%CI 0.62-0.66) and Brier-score of 0.04 (0.04-0.05). Calibration graphs show that it overestimates early-mortality. In temporal-validation, the AU-ROC was 0.61 (0.53-0.67).The selected update-method for ACC-TAVI was model-revision. In internal-validation, the AU-ROC was 0.63 (0.63-0.66) and Brier-score was 0.04 (0.04-0.05). The updated ACC-TAVI calibrates well up to a probability of 20%, and subsequently underestimates early-mortality. In temporal-validation the AU-ROC was 0.65 (0.58-0.72). CONCLUSION: Internal-validation of the updated models FRANCE-2 and ACC-TAVI with data from the NHR demonstrated improved performance, which was better than in external-validation studies and comparable to the original studies. In temporal-validation, ACC-TAVI outperformed FRANCE-2 because it suffered less from changes over time.
RESUMEN
In a 71-year-old female with evolving anterior wall myocardial infarction, coronary angiography revealed a monocoronary artery which arose from the right sinus of Valsalva. Originating from a short common trunk, the left main stem showed a thrombotic lesion that occluded the left anterior descending coronary artery while the circumflex artery was obstructed. Intracoronary administration of abciximab, followed by stenting of the transition between the left anterior descending coronary artery and the main stem, and final kissing balloon inflation of the bifurcation resulted in an excellent angiographic result and favourable clinical outcome. (Neth Heart J 2009;17:274-6.).
RESUMEN
BACKGROUND: Percutaneous renal denervation (RDN) has recently been introduced as a treatment for therapy-resistant hypertension. Also, it has been suggested that RDN may be beneficial for other conditions characterised by increased sympathetic nerve activity. There are still many uncertainties with regard to efficacy, safety, predictors for success and long-term effects. To answer these important questions, we initiated a Dutch RDN registry aiming to collect data from all RDN procedures performed in the Netherlands. METHODS: The Dutch RDN registry is an ongoing investigator-initiated, prospective, multicentre cohort study. Twenty-six Dutch hospitals agreed to participate in this registry. All patients who undergo RDN, regardless of the clinical indication or device that is used, will be included. Data are currently being collected on eligibility and screening, treatment and follow-up. RESULTS: Procedures have been performed since August 2010. At present, data from 306 patients have been entered into the database. The main indication for RDN was hypertension (n = 302, 99%). Patients had a mean office blood pressure of 177/100 (±29/16) mmHg with a median use of three (range 0-8) blood pressure lowering drugs. Mean 24-hour blood pressure before RDN was 157/93 (±18/13) mmHg. RDN was performed with different devices, with the Simplicity™ catheter currently used most frequently. CONCLUSION: Here we report on the rationale and design of the Dutch RDN registry. Enrolment in this investigator-initiated study is ongoing. We present baseline characteristics of the first 306 participants.
Asunto(s)
Hipertensión/cirugía , Sistema de Registros , Arteria Renal/cirugía , Simpatectomía/estadística & datos numéricos , Anciano , Antihipertensivos/uso terapéutico , Presión Sanguínea , Femenino , Humanos , Hipertensión/tratamiento farmacológico , Masculino , Persona de Mediana Edad , Países Bajos/epidemiología , Periodo Preoperatorio , Estudios Prospectivos , Arteria Renal/inervación , Simpatectomía/métodos , Tiempo , Resultado del TratamientoRESUMEN
Postabsorptive resting metabolic rate (RMR) and diet-induced thermogenesis (DIT) were repeatedly assessed with an indirect calorimetric ventilated hood system in a group of 32 healthy premenopausal obese women, body fat percentage 46.4 +/- 0.9 (mean +/- SEM), age 38.5 +/- 0.9 years. RMR and DIT were also measured in a group of 10 healthy premenopausal non-obese women, body fat percentage 31.3 +/- 1.7, age 37.7 +/- 2.4 years. The obese women were subdivided according to the waist-to-hips girth ratio (WHR) into three groups with a different type of body fat distribution: A gluteal-femoral obese group (n = 10), WHR less than 0.79; an intermediate obese group (n = 10), 0.79 less than WHR less than 0.85; and an abdominal obese group (n = 12), WHR greater than 0.85. No significant differences were observed among the obese groups in age, body weight, body fat mass, and fat-free body mass. Body fat distribution was not associated with differences in DIT, pre- and postprandial respiratory quotients and substrate oxidation rates, but the abdominal obese women had significantly higher RMRs adjusted for age, fat mass, and fat-free body mass (6,075 +/- 200 kJ/d) in comparison with the gluteal-femoral obese women (5,502 +/- 205 kJ/d) and in comparison with obese women with an intermediate body fat distribution (5,517 +/- 193 kJ/d), but not in comparison with a non-obese control group, 6,790 +/- 261 kJ/d. It is concluded that within the total group of obese women, the non-abdominal obese can be characterized by relatively reduced resting metabolic rates in comparison with either the abdominal obese or with non-obese women.
Asunto(s)
Tejido Adiposo/metabolismo , Metabolismo Basal , Grasas de la Dieta/metabolismo , Obesidad/metabolismo , Tejido Adiposo Pardo/metabolismo , Adulto , Factores de Edad , Glucemia/metabolismo , Composición Corporal , Calorimetría Indirecta , Ingestión de Alimentos , Metabolismo Energético , Femenino , Humanos , Absorción Intestinal , Metabolismo de los Lípidos , Obesidad/sangre , Transporte Respiratorio , Grosor de los Pliegues Cutáneos , SomatotiposRESUMEN
BACKGROUND: Little is known about the differences between the corrected thrombolysis in myocardial infarction (TIMI) frame count (CTFC) and the 'frame count velocity' (FCV), an estimate of blood flow velocity derived from the TFC and the length of the related vessel, in each of the three epicardial coronary arteries. METHODS: After angioplasty of 119 coronary vessels, 50 left anterior descending (LAD), 27 left circumflex (LCX) and 42 right coronary arteries (RCA), the CTFC was compared with the FCV assessed by measuring the length of the coronary arteries with an intracoronary guidewire. RESULTS: The three vessels show a significant difference in mean length (the LAD was 14.5±1.6 cm, LCX 12.8±1.9 cm and RCA 11.3±1.4 cm, p<0.001 for all comparisons), making it possible to convert the TFC to the FCV with reasonable accuracy without having to use a guidewire. The mean length of the LCX and the RCA was found to be considerably longer than in previous reports on which the CTFC is based. In addition, with this method the estimation of the coronary blood flow velocity in the RCA is significantly higher compared with the LAD and LCX (23.0±7.9 cm/sec versus 17.6±7.4 cm/sec and 16.4±6.3 cm/sec, respectively, p<0.001). CONCLUSION: With the TFC and the average length of the related coronary artery presented in this study, the FCV can be calculated for each of the three vessels resulting in a simple and, compared with the CTFC, more accurate angiographic estimation of the coronary blood flow velocity.
RESUMEN
Three dimensional coronary modeling and reconstruction can assist in the quantitative analysis of coronary flow velocity from 2-d coronary images. In this paper a novel method to assess coronary flow velocity is proposed. First, 3-d models of the coronary arteries are estimated from bi-plane X-ray images using epipolar constraint energy minimization for the selected fiducial points like bifurcations, and subsequently 3-d B-spline energy minimization for the arterial segments. A 4-d model is assembled from a set of 3-d models representing different phases of the cardiac cycle. The 4-d model is fitted to the 2-d image sequences containing basal or hyperemic blood flow information. Then, by counting the frames in analogy with TIMI frame counting, an index of the mean coronary flow velocity can be estimated. Our experimental results show that the algorithm correlates with r=0.98 (P<0.0001, 95% CI 0.92-0.99) to the clinical measurements of the TFC.
Asunto(s)
Algoritmos , Angiografía Coronaria/métodos , Circulación Coronaria/fisiología , Vasos Coronarios/diagnóstico por imagen , Interpretación de Imagen Asistida por Computador/métodos , Imagenología Tridimensional , Velocidad del Flujo Sanguíneo/fisiología , Medios de Contraste , Humanos , Procesamiento de Imagen Asistido por ComputadorRESUMEN
Background. Absence of complete ST-segment resolution (STR) after percutaneous coronary intervention (PCI) for ST-segment-elevation myocardial infarction (STEMI) is a determinant of mortality. Traditionally, STR is determined on the coronary care unit (CCU) 60 to 90 minutes after the initiation of reperfusion therapy. We studied the prognostic value of STR immediately after PCI. Methods. We analysed 223 consecutive patients with STEMI and successful PCI. Continuous ECG data were collected during PCI and at 30 minutes after arrival on the CCU (mean time 81±17 minutes after reflow of the culprit artery). Patients were divided into three groups: patients with complete STR immediately after PCI ('early'), patients with complete and persistent STR at 30 minutes on the CCU, but not immediately after PCI ('late') and patients without STR. One-year follow-up was obtained for death and rehospitalisation for major adverse cardiac events. Cox proportional hazards regression was used to evaluate the association between STR and outcome. Results. Early STR occurred in 115 (52%) and late STR in 43 (19%) patients. Patients with early or late STR had a lower incidence of one-year cardiac death than those without STR (1.9 vs. 9.2%; p=0.02). In contrast, rehospitalisation occurred more frequently in patients with early or late STR (20.3 vs. 6.2%; p=0.009). As compared with patients without STR, early and late STR had a similar prognostic value (hazard ratios [95% confidence interval] for cardiac death 0.40 [0.08-2.03] and 0.25 [0.03-2.08]).Conclusions. We found no (major) change in prognostic value of STR during the 0 to 90 minutes time window after PCI. (Neth Heart J 2010;18:416-22.).
RESUMEN
Background. New-generation drug-eluting stents (DES) may solve several problems encountered with first-generation DES, but there is a lack of prospective head-to-head comparisons between new-generation DES. In addition, the outcome of regulatory trials may not perfectly reflect the outcome in 'real world' patients.Objectives. To compare the efficacy and safety of two new-generation DES in a 'real world' patient population.Methods. A prospective, randomised, single-blinded clinical trial to evaluate clinical outcome after Endeavor Resolute vs. Xience V stent implantation. The primary endpoint is target vessel failure at one-year follow-up. In addition, the study comprises a two-year and an open-label five-year follow-up. (Neth Heart J 2010;18:360-4.).